Merck, on Monday, announced the successful completion of the acquisition of Acceleron Pharma. The new addition to Merck will strengthen its cardiovascular portfolio. The firm is expecting to reach more people suffering from critical health issues.
“This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy,”said Rob Davis, chief executive officer and president, Merck
Davis further says, “Fueled by Acceleron’s groundbreaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need.”
Acceleron is currently working on a soluble fusion protein that has the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH).
PAH is a progressive and life-threatening blood vessel disorder. Sotatercept is in Phase 3 trials as an add-on to the current standard of care for the treatment of PAH.
See the Tweet Here: